Few medical topics have been more distorted by headlines than the relationship between hormone replacement therapy and breast cancer. A 2002 study caused hundreds of thousands of women to stop HRT overnight — leading to measurably worse quality of life for many, and later analysis suggesting some of the initial data was misinterpreted. Two decades on, the evidence is clearer and the NHS and NICE guidance is more nuanced. This is what it actually says.
What the evidence shows: risk by HRT type
- Oestrogen-only HRT: little to no increased breast cancer risk. Usually only prescribed to women who have had a hysterectomy, as it carries a separate risk of endometrial cancer in women with a womb.
- Combined HRT (oestrogen + progestogen): small increased risk that grows with duration of use. This is the most commonly prescribed type.
- Vaginal or topical oestrogen (local HRT): very low doses absorbed locally for symptoms like dryness. No increased breast cancer risk.
- Body-identical HRT with micronised progesterone: emerging evidence from France and large observational studies suggests lower breast cancer risk than synthetic progestogen-based combined HRT. Longer-term randomised data are still accumulating.
What the absolute numbers actually mean
The word 'increased risk' triggers alarm, but relative risk statistics are routinely misunderstood. A '30% increased risk' sounds dramatic. In absolute terms, for a woman in her 50s taking combined HRT for 5 years, the estimated absolute increase in breast cancer risk is approximately 4 extra cases per 1,000 women — from roughly 23 cases to roughly 27 cases per 1,000. This is a real increase, but it is comparable in magnitude to the risk increase from drinking one glass of wine per day, or from being overweight after menopause. Neither of those factors typically generates the same level of alarm.
Around 2 in every 100 breast cancers in the UK — about 1,100 cases per year — are estimated to be associated with HRT use. This needs to be set against the benefits: substantial improvement in quality of life, reduced osteoporosis risk, and emerging evidence of cardiovascular protection for women who start HRT before age 60.
What NHS and NICE guidance actually says
NICE guideline NG23 (Menopause: diagnosis and management) states clearly: for most women under 60 who are within 10 years of menopause and have no contraindications, the benefits of HRT outweigh the risks. The guidance recommends that women be given accurate information about both the absolute risks and the benefits — not just headlines about risk. It also states that HRT should not be viewed as a blanket no for cancer history; each case must be considered individually.
How quickly does risk fall after stopping?
The increased breast cancer risk associated with combined HRT begins to decline once treatment is stopped. It returns close to baseline — that of a woman who never took HRT — within approximately 5 years of stopping. Women who took combined HRT for less than one year have very little measurable lasting increased risk. This is important context for women who may have taken HRT briefly during early menopause and are now wondering about their risk years later.
Can you take HRT after breast cancer?
For most breast cancer survivors, combined systemic HRT is not recommended because oestrogen can potentially stimulate hormone receptor-positive residual cancer cells. This applies to approximately 80% of breast cancers, which are ER+. However, vaginal oestrogen — used in very low doses for local symptoms like dryness and discomfort — is generally considered much lower risk, and many breast cancer survivors use it with specialist agreement. This is a conversation to have with your oncologist or breast care team, not a blanket prohibition.
The context that rarely makes headlines
The debate about whether to take HRT — weighing a small increased breast cancer risk against meaningful relief from menopausal symptoms — is a conversation that happens from a position of extraordinary privilege. Women in the UK can access their GP, discuss their individual risk profile, read NICE guidelines, and make an informed decision with a qualified clinician. This is not a given.
In low-income communities across the developing world — where Breast Cancer Awareness works — most women have never had a breast examination. When breast cancer is found, it is almost always at Stage III or Stage IV because no organised screening exists. The five-year survival rate in those communities is below 40%. In the UK it is over 85%. That gap is not biological. It is access. A donation of £25 funds one complete breast cancer screening for a woman who may never otherwise be examined. Please consider donating today.
